Covis Pharma appeared to make a mid-hearing strategy shift on what it wants the US Food and Drug Administration to do with the approval of its preterm birth drug Makena, which the company is trying to save from complete market withdrawal by proposing a narrower indication.
The move might have been a swift attempt by Covis to try and climb itself out of a hole the...